Top

Published in:

01-09-2014 | Portal Hypertension (JC Garica-Pagán, Section Editor)

Invasive and Non-invasive Diagnosis of Portal Hypertension in Cirrhosis

Authors: Bogdan Procopet, Christophe Bureau

Published in: Current Hepatology Reports | Issue 3/2014

Abstract

In the natural history of any chronic liver disease the occurrence of liver related complications is related to the portal hypertension development. Therefore, in the diagnosis work up of any liver disease the portal hypertension assessment is an indispensable step. The most accurate method for portal hypertension diagnosis is hepatic venous pressure gradient (HVPG), which implies central venous access and the catheterization of the hepatic vein. HVPG is the strongest prognostic marker in chronic liver diseases. It accurately predicts the risk of esophageal varices development and hemorrhage, the risk of decompensation as well as the mortality. Also HVPG represents a method to tailor portal hypertension treatment. However, due to the invasiveness of the procedure, there is an extensive effort to find non-invasive methods that could replace HVPG measurement. By now, only liver stiffness measuring proves to have good performances even there are issues about cut-offs and feasibility in overweight patients.

1.••

D’Amico G, Stages Classification of Cirrhosis: Where Do We Stand? in: de Franchis R Portal Hypertension V: Proceedings of the Fifth Baveno International Consensus Workshop, Fifth Edition. Blackwell Publishing Ltd; 2011. p. 132–9. New concepts in the natural history of cirrhosis.

2.•

Rosselli M, Macnaughtan J, Jalan R, Pinzani M. Beyond scoring: a modern interpretation of disease progression in chronic liver disease. Gut. 2013;62:1234–41. New concepts in the stages of chronic liver diseases.PubMedCrossRef

Paton A, Reynolds T, Sherlock S. Assessment of portal venous hypertension by catheterisation of hepatic vein. Lancet. 1953;1:918–21.PubMedCrossRef

Thalheimer U, Leandro G, Samonakis DN, et al. Assessment of the agreement between wedge hepatic vein pressure and portal vein pressure in cirrhotic patients. Dig Liver Dis. 2005;37:601–8.PubMedCrossRef

Groszmann RJ, Wongcharatrawee S. The Hepatic Venous Pressure Gradient. Hepatology. 2004;39:280–5.PubMedCrossRef

6.•

Reverter E, Blasi A, Abraldes JG, Mart G. Impact of deep sedation on the accuracy of hepatic and portal venous pressure measurements in patients with cirrhosis. Liver Int. 2013;7:1–10. Important details about how to measure HVPG regarding the level of sedetation.

Groszmann RJ, Glickman M, Blei AT, Storer E, Conn HO. Wedged and free hepatic venous pressure measured with a balloon catheter. Gastroenterology. 1979;76:253–8.PubMed

Maleux G, Willems E, Fieuws S, et al. Prospective study comparing different indirect methods to measure portal pressure. J Vasc Interv Radiol. 2011;8:1553–8.CrossRef

Zipprich A, Winkler M, Seufferlein T, Dollinger MM. Comparison of balloon vs straight catheter for the measurement of portal hypertension. Aliment Pharmacol Ther. 2010;32:1351–6.PubMedCrossRef

10.

Bosch J, Abraldes JG, Berzigotti A, Garcia-Pagan JC. The clinical use of HVPG measurements in chronic liver disease. Nat Rev Gastroenterol Hepatol. 2009;6:573–82.PubMedCrossRef

11.•

Procopet B, Bureau C, Métivier S, et al. Tolerance of liver biopsy in a tertiary care center: comparison of the percutaneous and the transvenous route in 143 prospectively followed patients. Eur J Gastroenterol Hepatol. 2012;24:1209–13. Demonstrate the good tolerance of the patients to the jugular approach.PubMedCrossRef

12.

Berzigotti A, Seijo S, Reverter E, Bosch J. Assessing portal hypertension in liver diseases. Expert Rev Gastroenterol Hepatol. 2013;7:141–55.PubMedCrossRef

13.

Kumar M, Kumar A, Hissar S, et al. Hepatic venous pressure gradient as a predictor of fibrosis in chronic liver disease because of hepatitis B virus. Liver Int. 2008;28:690–8.PubMedCrossRef

14.

Garcia-Tsao G, Rodriguez-Perez FBA. Treatement with interferon reduces portal pressure in patients with chronic hepatitis C. A randomized placebo trial Gastroenterology. 1996;10:A1193.

15.

Rincon D, Ripoll C, Lo Iacono O, et al. Antiviral therapy decreases hepatic venous pressure gradient in patients with chronic hepatitis C and advanced fibrosis. Am J Gastroenterol. 2006;101:2269–74.PubMedCrossRef

16.

Roberts S, Gordon A, McLean C, et al. Effect of sustained viral response on hepatic venous pressure gradient in hepatitis C-related cirrhosis. Clin Gastroenterol Hepatol. 2007;5:932–7.PubMedCrossRef

17.

Blasco A, Forns X, Carrion JA, et al. Hepatic venous pressure gradient identifies patients at risk of severe hepatitis C recurrence after liver transplantation. Hepatology. 2006;43:492–9.PubMedCrossRef

18.

Nagula S, Jain D, Groszmann RJ, Garcia-Tsao G. Histological-hemodynamic correlation in cirrhosis-a histological classification of the severity of cirrhosis. J Hepatol. 2006;44:111–7.PubMedCrossRef

19.

Kumar M, Sakhuja P, Kumar A, et al. Histological subclassification of cirrhosis based on histological – haemodynamic correlation. Aliment Pharmacol Ther. 2008;27:771–9.PubMedCrossRef

20.

Rincon D, Lo Iacono O, Ripoll C, et al. Prognostic value of hepatic venous pressure gradient for in-hospital mortality of patients with severe acute alcoholic hepatitis. Aliment Pharmacol Ther. 2007;25:841–8.PubMedCrossRef

21.

Vorobioff J, Groszmann RJ, Picabea E, et al. Prognostic value of hepatic venous pressure gradient measurements in alcoholic cirrhosis: a 10-year prospective study. Gastroenterology. 1996;111:701–9.PubMedCrossRef

22.

Ripoll C, Groszmann R, Garcia-Tsao G, et al. Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis. Gastroenterology. 2007;133:481–8.PubMedCrossRef

23.••

Robic MA, Procopet B, Métivier S, et al. Liver stiffness accurately predicts portal hypertension related complications in patients with chronic liver disease: a prospective study. J Hepatol. 2011;55:1017–24. First paper that demonstrates prognostic value of liver stiffness measurement in patients with chronic liver diseases.PubMedCrossRef

24.

Groszmann RJ, Garcia-Tsao G, Bosch J, et al. Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis. N Engl J Med. 2005;353:2254–61.PubMedCrossRef

25.

Garcia-Tsao G, Groszmann RJ, Fisher RL, et al. Portal pressure, presence of gastroesophageal varices and variceal bleeding. Hepatology. 1985;5:419–24.PubMedCrossRef

26.

Groszmann RJ, Bosch J, Grace ND, et al. Hemodynamic events in a prospective randomized trial of propranolol versus placebo in the prevention of a first variceal hemorrhage. Gastroenterology. 1990;99:1401–7.PubMed

27.

Casado M, Bosch J, Garcia-Pagan JC, et al. Clinical events after transjugular intrahepatic portosystemic shunt: correlation with hemodynamic findings. Am J Gastroenterol. 1998;114:1296–303.

28.

Monescillo A, Martínez-Lagares F, Ruiz-del-Arbol L, et al. Influence of portal hypertension and its early decompression by TIPS placement on the outcome of variceal bleeding. Hepatology. 2004;40:793–801.PubMedCrossRef

29.

Abraldes JG, Villanueva C, Bañares R, et al. Hepatic venous pressure gradient and prognosis in patients with acute variceal bleeding treated with pharmacologic and endoscopic therapy. J Hepatol. 2008;48:229–36.PubMedCrossRef

30.

Moitinho E, Escorsell A, Bandi JC, et al. Prognostic value of early measurements of portal pressure in acute variceal bleeding. Gastroenterology. 1999;117:626–31.PubMedCrossRef

31.

Garcia-Pagan JC, Karel C, Bureau C, et al. Early TIPS in patients with cirrhosis and variceal bleeding. N Engl J Med. 2010;7:536–8.

32.••

Garcia-Pagán JC, Di PM, Caca K, et al. Use of early-TIPS for high-risk variceal bleeding: Results of a post-RCT surveillance study. J Hepatol. 2013;58:4–9. Comfirms the privivous data and, therefore, highlights the importance of the clinical problem.CrossRef

33.

Hernández-Gea V, Aracil C, Colomo A, et al. Development of ascites in compensated cirrhosis with severe portal hypertension treated with β-blockers. Am J Gastroenterol. 2012;107:418–27.PubMedCrossRef

34.

Abraldes JG, Tarantino I, Turnes J, et al. Hemodynamic response to pharmacological treatment of portal hypertension and long-term prognosis of cirrhosis. Hepatology. 2003;37:902–8.PubMedCrossRef

35.

Villanueva C, Planella M, Aracil C, et al. Hemodynamic effects of terlipressin and high somatostatin dose during acute variceal bleeding in nonresponders to the usual somatostatin dose. Am J Gastroenterol. 2005;100:624–30.PubMedCrossRef

36.

Bureau C, Alric JL, Morales J, et al. A La Carte” Treatment of Portal Hypertension: Adapting Medical Therapy to Hemodynamic Response for the Prevention of Bleeding. Hepatology. 2002;1053:1361–6.CrossRef

37.

Gonzales A, Augustin S, Mercedes P, et al. Hemodynamic Response–Guided Therapy for Prevention of Variceal Rebleeding: An Uncontrolled Pilot Study. Hepatology. 2006;44:806–12.CrossRef

38.••

Reiberger T, Ulbrich G, Ferlitsch A, et al. Carvedilol for primary prophylaxis of variceal bleeding in cirrhotic patients with haemodynamic non-response to propranolol. Gut. 2013;62:1634–41. Demonstrates that Carvedilol may recruts patient with treatment respons among non-responders to propranolol and that Carvedilol is efficient in primary prophylaxis of esophageal varices hemorrhage.PubMedCrossRef

39.

Albillos A, Banares R, Gonzalez M, et al. Value of the hepatic venous pressure gradient to monitor drug therapy for portal hypertension: a meta-analysis. Am J Gastroenterol. 2007;102:1116–26.PubMedCrossRef

40.

Targownik LE, Spiegel BMR, Dulai GS, et al. The Cost-Effectiveness of hepatic venous pressure gradient monitoring in the prevention of recurrent variceal hemorrhage. Am J Gastroenterol. 2004;15:1308–15.

41.

Villanueva C, López-Balaguer JM, Aracil C, et al. Maintenance of hemodynamic response to treatment for portal hypertension and influence on complications of cirrhosis. J Hepatol. 2004;40:757–65.PubMedCrossRef

42.

Merkel C, Bolognesi M, Berzigotti A, et al. Clinical significance of worsening portal hypertension during long-term medical treatment in patients with cirrhosis who had been classified as early good-responders on haemodynamic criteria. J Hepatol. 2010;52:45–53.PubMedCrossRef

43.

Bruix J, Castells A, Bosch J, et al. Surgical resection of hepatocellular carcinoma in cirrhotic patients: prognostic value of preoperative portal pressure. Gastroenterology. 1996;111:1018–22.PubMedCrossRef

44.

Llovet JM, Fuster J, Bruix J. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology. 1999;30:1434–40.PubMedCrossRef

45.

Figueras J, Llado L, Ruiz D, et al. Complete versus selective portal triad clamping for minor liver resections. Ann Surg. 2005;2414:582–90.CrossRef

46.

Boleslawski E, Petrovai G, Truant S, et al. Hepatic venous pressure gradient in the assessment of portal hypertension before liver resection in patients with cirrhosis. Br J Surg. 2012;99:855–63.PubMedCrossRef

47.

Stremitzer S, Tamandl D, Kaczirek K, et al. Value of hepatic venous pressure gradient measurement before liver resection for hepatocellular carcinoma. Br J Surg. 2011;98:1752–8.PubMedCrossRef

48.••

Llop E, Berzigotti A, Reig M, et al. Assessment of portal hypertension by transient elastography in patients with compensated cirrhosis and potentially resectable liver tumors. J Hepatol. 2012;56:103–8. First aplication of liver stiffness measurement in risk assessment of patients referet to hepatocellular resection.PubMedCrossRef

49.

EASL-EORT Clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56:908–943.

50.

Thabut D, Imbert-Bismut F, Cazals-Hatem D, et al. Relationship between the Fibrotest and portal hypertension in patients with liver disease. Aliment Pharmacol Ther. 2007;26:359–68.PubMedCrossRef

51.

Berzigotti A, Gilabert R, Abraldes JG, et al. Noninvasive prediction of clinically significant portal hypertension and esophageal varices in patients with compensated liver cirrhosis. Am J Gastroenterol. 2008;103:1159–67.PubMedCrossRef

52.

Bureau C, Metivier S, Peron JM, et al. Transient elastography accurately predicts presence of significant portal hypertension in patients with chronic liver disease. Aliment Pharmacol Ther. 2008;27:1261–8.PubMedCrossRef

53.

Castera L, Le Bail B, Roudot-Thoraval F, et al. Early detection in routine clinical practice of cirrhosis and oesophageal varices in chronic hepatitis C: Comparison of transient elastography (FibroScan) with standard laboratory tests and non-invasive scores. J Hepatol. 2009;50:59–68.PubMedCrossRef

54.

Park SH, Park TE, Kim YM, et al. Non-invasive model predicting clinically-significant portal hypertension in patients with advanced fibrosis. J Gastroenterol Hepatol. 2009;24:1289–93.PubMedCrossRef

55.

Naveau S, Gaudé G, Asnacios A, et al. Diagnostic and prognostic values of noninvasive biomarkers of fibrosis in patients with alcoholic liver disease. Hepatology. 2009;49:97–105.PubMedCrossRef

56.••

Vergniol J, Foucher J, Terrebonne E, et al. Noninvasive tests for fibrosis and liver stiffness predict 5-year outcomes of patients with chronic hepatitis C. Gastroenterology. 2011;140:1970–9. Long term follow-up study demonstrating the prognostic relevance of liver stiffness.PubMedCrossRef

57.

Berzigotti A, Bru Saumell C, Gilabert Sole R. Ultrasound in the non-invasive evaluation of fibrosis and portal hypertension. in: de Franchis R Portal Hypertension V: Proceedings of the Fifth Baveno International Consensus Workshop, Fifth Edition. Blackwell Publishing Ltd; 2011. p. 28-36.

58.

Sandrin L, Fourquet B, Hasquenoph JM, et al. Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol. 2003;29:1705–13.PubMedCrossRef

59.

Friedrich-Rust M, Ong M-F, Martens S, et al. Performance of transient elastography for the staging of liver fibrosis: a meta-analysis. Gastroenterology. 2008;134:960–794.PubMedCrossRef

60.

Tsochatzis EA, Gurusamy KS, Ntaoula S, et al. Elastography for the diagnosis of severity of fibrosis in chronic liver disease: a meta-analysis of diagnostic accuracy. J Hepatol. 2011;54:650–9.PubMedCrossRef

61.

Carrion J, Navasa M, Bosch J, et al. Transient elastography for diagnosis of advanced fibrosis and portal hypertension in patients with hepatitis C recurrence after liver transplantation. Liver Transpl. 2006;12:1791–8.PubMedCrossRef

62.

Vizzutti F, Arena U, Romanelli RG, et al. Liver stiffness measurement predicts severe portal hypertension in patients with HCV-related cirrhosis. Hepatology. 2007;45:1290–7.PubMedCrossRef

63.

Lemoine M, Katsahian S, Ziol M, et al. Liver stiffness measurement as a predictive tool of clinically significant portal hypertension in patients with compensated hepatitis C virus or alcohol-related cirrhosis. Aliment Pharmacol Ther. 2008;28:1102–10.PubMedCrossRef

64.

Sanchez-Conde M, Miralles P, Marıa Bellon J, et al. Use of transient elastography ( FibroScan Ò ) for the noninvasive assessment of portal hypertension in HIV / HCV-coinfected patients. J Viral Hepat. 2011;18:685–91.PubMedCrossRef

65.

Reiberger T, Ferlitsch A, Payer BA, et al. Noninvasive screening for liver fibrosis and portal hypertension by transient elastography — a large single center experience. Wien Klin Wochenschr. 2012;124:395–402.PubMedCrossRef

66.••

Berzigotti A, Seijo S, Arena U, et al. Elastography, spleen size, and platelet count identify portal hypertension in patients with compensated cirrhosis. Gastroenterology. 2013;144:102–11. A rigouros validation of a novel score including liver stiffness and laboratory findings in diagnosis of CSPHT.PubMedCrossRef

67.••

Shi K, Fan Y, Pan Z, et al. Transient elastography : a meta-analysis of diagnostic accuracy in evaluation of portal hypertension in chronic liver disease. Liver Int. 2013;33:62–71. First meta-analysis of five studies demonstrating the role of liver stiffness in CSPHT diagnosis.PubMedCrossRef

68.

Corpechot C, Carrat F, Poujol-Robert A, et al. Noninvasive elastography-based assessment of liver fibrosis progression and prognosis in primary biliary cirrhosis. Hepatology. 2012;56:198–208.PubMedCrossRef

69.

Singh S, Fujii LL, Murad MH, et al. Liver stiffness measurements are associated with risk of decompensation, liver cancer, and death in patients with chronic liver diseases: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2013;11:1573–84.PubMedCrossRef

70.

Pesce A, Scilletta R, Branca A, et al. Does transient elastography (FibroScan ®) have a role in decision making in hepatocellular carcinoma ? HPB. 2012;14:403–8.PubMedCentralPubMedCrossRef

71.

Castera L, Foucher J, Bernard PH, et al. Pitfalls of liver stiffness measurement: a 5-year prospective study of 13,369 examinations. Hepatology. 2010;51:828–35.PubMed

72.

Arena U, Vizzutti F, Corti G, et al. Acute viral hepatitis increases liver stiffness values measured by transient elastography. Hepatology. 2008;47:380–4.PubMedCrossRef

73.

Lebray P, Varnous S, Charlotte F, et al. Liver stiffness is an unreliable marker of liver fibrosis in patients with cardiac insufficiency. Hepatology. 2008;48:2089.PubMedCrossRef

74.••

Berzigotti A, De GA, Vukotic R, et al. Effect of meal ingestion on liver stiffness in patients with cirrhosis and portal hypertension. PLoS One. 2013;8:1–5. Demonstrating that liver stiffness should be measured in fasting conditions.CrossRef

75.••

Arena U, Platon ML, Stasi C, et al. Liver Stiffness Is Influenced by a Standardized Meal in Patients With Chronic Hepatitis C Virus at Different Stages of Fibrotic Evolution. Hepatology. 2013;58:65–72. Demonstrating that liver stiffness should be measured in fasting conditions.PubMedCrossRef

76.

Stefanescu H, Grigorescu M, Lupsor M, et al. Spleen stiffness measurement using Fibroscan for the noninvasive assessment of esophageal varices in liver cirrhosis patients. J Gastroenterol Hepatol. 2011;26:164–70. **[first report of spleen stiffness measurement in chronic liver diseases].PubMedCrossRef

77.••

Colecchia A, Montrone L, Scaioli E, et al. Measurement of spleen stiffness to evaluate portal hypertension and the presence of esophageal varices in patients with HCV-related cirrhosis. Gastroenterology. 2012;143:646–54. First report of the correlation between spleen stiffness and HVPG.PubMedCrossRef

78.

Stefanescu H, Procopet B, Platon-Lupsor M, Bureau C. Is there any place for spleen stiffness measurement in portal hypertension ? Am J Gastroenterol. 2013;108:1660–1.PubMedCrossRef

79.

Sharma P, Kirnake V, Tyagi P, et al. Spleen stiffness in patients with cirrhosis in predicting esophageal varices. Am J Gastroenterol. 2013;108:1101–7.PubMedCrossRef

80.

Ferlitsch A, Salzl P, Reiberger T, et al. Comparison of liver stiffness assessment by Fibroscan and Acoustic Radiation Force Impulse Imaging for the evaluation of liver fibrosis and cirrhosis. Z Gastroenterol. 2010;48:P4.CrossRef

81.

Borghi A, Piscaglia F, Venerandi L, et al. Splenic stiffness assessed by ARFI (acoustic radiation force imaging) correlates with portal pressure in cirrhosis. J Hepatol. 2012;56:S234–5.CrossRef

82.

Takuma Y, Nouso K, Morimoto Y, et al. Measurement of spleen stiffness by acoustic radiation force impulse imaging identifies cirrhotic patients with esophageal varices. Gastroenterology. 2013;144:92–101.PubMedCrossRef

83.

Ye XP, Ran HT, Cheng J, et al. Liver and spleen stiffness measured by acoustic radiation force impulse elastography for noninvasive assessment of liver fibrosis and esophageal varices in patients with chronic hepatitis B. J Ultrasound Med. 2012;31:1245–53.PubMed

84.

Rifai K, Cornberg J, Bahr M, et al. ARFI elastography of the spleen is inferior to liver elastography for the detection of portal hypertension. Ultraschall Med. 2011;32 Suppl 2:E24–30.PubMedCrossRef

85.

Furuichi Y, Moriyasu F, Taira J, et al. Noninvasive diagnostic method for idiopathic portal hypertension based on measurements of liver and spleen stiffness by ARFI elastography. J Gastroenterol. 2013;48:1061–8.PubMedCrossRef

86.

Hirooka M, Ochi H, Koizumi Y, et al. Splenic elasticity measured with real-time tissue elastography is a marker of portal hypertension. Radiology. 2011;261:960–8.PubMedCrossRef

87.

Giannini E, Botta F, Borro P, et al. Platelet count/spleen diameter ratio: proposal and validation of a non-invasive parameter to predict the presence of oesophageal varices in patients with liver cirrhosis. Gut. 2003;52:1200–5.PubMedCentralPubMedCrossRef

88.

Giannini EG, Zaman A, Kreil A, et al. Platelet count/spleen diameter ratio for the noninvasive diagnosis of esophageal varices: results of a multicenter, prospective, validation study. Am J Gastroenterol. 2006;101:2511–9.PubMedCrossRef

89.

Mangone M, Moretti A, Alivernini F, et al. Platelet count/spleen diameter ratio for non-invasive diagnosis of oesophageal varices: is it useful in compensated cirrhosis? Dig Liver Dis. 2012;44:504–7.PubMedCrossRef

90.

Schwarzenberger E, Meyer T, Golla V, et al. Utilization of platelet count spleen diameter ratio in predicting the presence of esophageal varices in patients with cirrhosis. J Clin Gastroenterol. 2010;44:146–50.PubMedCrossRef

91.

Chawla S, Katz A, Attar BM, et al. Platelet count/spleen diameter ratio to predict the presence of esophageal varices in patients with cirrhosis: a systematic review. Eur J Gastroenterol Hepatol. 2012;24:431–6.PubMed

92.

Kim BK, Han K-H, Park JY, et al. A liver stiffness measurement-based, noninvasive prediction model for high-risk esophageal varices in B-viral liver cirrhosis. Am J Gastroenterol. 2010;105:1382–90.PubMedCrossRef

93.

Sebastiani G, Halfon P, Castera L, et al. SAFE biopsy: a validated method for large-scale staging of liver fibrosis in chronic hepatitis C. Hepatology. 2009;49:1821–7.PubMedCrossRef

94.

Stefanescu H, Grigorescu M, Lupsor M, et al. A new and simple algorithm for the noninvasive assessment of esophageal varices in cirrhotic patients using serum fibrosis markers and transient elastography. J Gastrointest liver Dis. 2011;20:57–64.

95.

De Franchis R. Revising consensus in portal hypertension: report of the Baveno V consensus workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol. 2010;53:762–8.PubMedCrossRef

96.

Corpechot C, Gaouar F, El Naggar A, et al. Baseline values and changes in liver stiffness measured by transient elastography are associated with severity of fibrosis and outcomes of patients with primary sclerosing cholangitis. Gastroenterology. 2014;146:970–9. First paper that demonstrates the potential rol of serial liver stiffness measuremnts in prognosis of chronic liver diseases].

Title: Invasive and Non-invasive Diagnosis of Portal Hypertension in Cirrhosis
Authors: Bogdan Procopet
Christophe Bureau
Publication date: 01-09-2014
Publisher: Springer US
Published in: Current Hepatology Reports / Issue 3/2014
Electronic ISSN: 2195-9595
DOI: https://doi.org/10.1007/s11901-014-0237-3

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2014

Immunosuppression in Patients with Chronic Hepatitis B

From Refractory Ascites to Dilutional Hyponatremia and Hepatorenal Syndrome: Current Options for Treatment

Splanchnic and Extrasplanchnic Thrombosis in Cirrhosis: Prophylaxis vs Treatment

Response-guided Peginterferon Therapy for HBeAg-positive and HBeAg-negative Chronic Hepatitis B using Hepatitis B Surface Antigen Levels: A Review

Prognostic Factors in Compensated and Decompensated Cirrhosis

Can Nucleos(t)ide Analogue (NA) Therapy Ever be Stopped in HBeAg-Negative Chronic Hepatitis B?

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage